Fox Run Management L.L.C. Purchases 52,756 Shares of Cellebrite DI Ltd. $CLBT

Fox Run Management L.L.C. increased its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 293.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 70,742 shares of the company’s stock after buying an additional 52,756 shares during the period. Fox Run Management L.L.C.’s holdings in Cellebrite DI were worth $1,275,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Advisory Services Network LLC bought a new stake in shares of Cellebrite DI during the 3rd quarter worth $40,000. CWM LLC boosted its holdings in shares of Cellebrite DI by 57.0% during the 4th quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $44,000 after buying an additional 889 shares during the period. First Horizon Corp boosted its holdings in shares of Cellebrite DI by 421.8% during the 4th quarter. First Horizon Corp now owns 2,891 shares of the company’s stock worth $52,000 after buying an additional 2,337 shares during the period. Vestcor Inc bought a new stake in shares of Cellebrite DI during the 3rd quarter worth $70,000. Finally, PNC Financial Services Group Inc. boosted its holdings in shares of Cellebrite DI by 114.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 4,501 shares of the company’s stock worth $83,000 after buying an additional 2,403 shares during the period. 45.88% of the stock is owned by institutional investors.

Insider Activity

In other news, CRO Marcus Jewell sold 12,658 shares of the stock in a transaction on Monday, May 18th. The shares were sold at an average price of $12.77, for a total value of $161,642.66. Following the completion of the transaction, the executive owned 440,101 shares in the company, valued at approximately $5,620,089.77. This represents a 2.80% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders have sold 13,269 shares of company stock valued at $169,592. Corporate insiders own 5.70% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on CLBT shares. Wall Street Zen raised shares of Cellebrite DI from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Weiss Ratings upgraded shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Needham & Company LLC cut their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, May 15th. Finally, DA Davidson started coverage on shares of Cellebrite DI in a research note on Wednesday, May 27th. They set a “buy” rating and a $20.00 target price for the company. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $21.40.

Cellebrite DI Stock Performance

Shares of CLBT stock opened at $12.98 on Wednesday. Cellebrite DI Ltd. has a 52-week low of $11.02 and a 52-week high of $19.98. The stock has a market cap of $3.24 billion, a price-to-earnings ratio of 46.36, a P/E/G ratio of 1.66 and a beta of 1.17. The firm has a fifty day moving average of $13.27 and a 200-day moving average of $15.12.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.